Unlock the power of genetics

At Myriad Genetics, we believe in the power of human understanding. That’s why we offer a personal and thoughtful genetic insights experience for providers and the women who rely on them.

Myriad Women's Health Portals

Your partner in patient care

We provide transformative genetic insights that let you focus on what you do best, offering definitive results and support whenever you need it.

MyRisk® Hereditary Cancer Test

Help patients get ahead of cancer with our hereditary cancer test

Prequel® Prenatal Screen

Get reliable results the first time with noninvasive prenatal screening

Foresight® Carrier Screen

Identify couples at risk to pass down serious, prevalent, clinically-actionable inherited conditions

We’re reimagining the future of genetics


lower false positive rates from cfDNA screening compared to standard screening3

Learn why NIPS leads to fewer unnecessary invasive procedures


of affected pregnancies no longer missed1

Learn how ECS detects more at-risk couples for serious conditions

Why genetic screening and testing?

Supporting services with Myriad Complete

Myriad offers the following through Myriad Complete to help your patient navigate through the testing/screening process.


We provide resources to help educate your patients about Myriad products.


We offer a comprehensive program to make genetic products accessible for more of your patients.


We deliver screening and testing results effectively and thoroughly so you can focus on care plans.


We provide consults from patient educators, who are genetic counselors, tailored to help your patient understand their results.

All patients deserve genetic insights

At Myriad Genetics, you can count on us to do the heavy lifting in the moments that matter.


  1. Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018; doi:10.1373/clinchem.2018.286823
  2. Ghiossi, C.E., Goldberg, J.D., Haque, I.S. et al. J Genet Counsel (2017). https://doi.org/10.1007/s10897-017-0160-1.
  3. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597.
  4. BRCA1/BRCA2 Frequency: Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014.